ArticleOncoTargets and therapy2015

Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.

Hai Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.